Skip to NavigationSkip to content

J&J reportedly poised to acquire Europe’s biggest biotech

Published on 25/11/16 at 12:34pm

Johnson & Johnson could be eyeing a takeover of Swiss biotech Actelion, Europe’s biggest biotech, according to insiders, Bloomberg has reported.

The pharmaceutical and consumer goods manufacturer has reportedly made an initial offer of $17 billion, while Actelion is looking into potential options, though there is no obligation for a transaction to take place.

While Actelion has attracted attention over the years as a prime target for acquisition, CEO and co-founder Jean-Paul Clozel has repeatedly reaffirmed the company’s stance to remain independent. Shire stands among the latest to have their eye on the company, placing an offer of $15.4 billion to snatch up the company in June last year which was shot down.

The Swiss firm’s shares have risen by 13% over the past year thanks in part to strong sales from its new pulmonary arterial hypertension (PAH) treatments Opsumit and Uptravi.

This is another in a sequence of big-money takeovers for J&J, as the company only recently agreed to acquire Abbott Medical Optics for $4.33 billion in September this year, after announcing earlier that it had set aside $18.5 billion in cash to use in targeted acquisitions.

Neither company has committed to comment on the rumours.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches